The Zhitong Finance App learned that Junshi Biotech (01877) rose by more than 4%. As of press release, it had risen 3.94% to HK$19.79, with a turnover of HK$3.59 million.

According to the news, on August 26, Junshi Biotech announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 1,696 billion (same unit), an increase of 45.18% over the previous year; profit attributable to the owners of the company was 25.501 million yuan, which turned a loss into a profit over the previous year; and a profit of 0.02 yuan per share.

^{Among them: Pharmaceutical sales revenue was approximately $1,407 million, an increase of about 33% over the same period in 2025. The increase was mainly due to improved sales efficiency of the commercialization team and approval of more Tuoyi® indications; revenue related to licensing agreements of approximately $254 million; and revenue from technical services and other businesses of approximately $35 million.}

During the reporting period, Tuoyi ^®'s domestic sales revenue was approximately $1,299 million, an increase of about 36% over the same period in 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.